C

    Compass Therapeutics Inc. (CMPX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.39
    -0.01 (-0.42%)

    Market Cap: $430.41M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    52%(11/21)
    Avg Surprise
    -4.27%

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.13
    Range$-0.15 - $-0.10
    11 analysts
    EPS RevisionsNo revisions (7d)
    0
    4
    30d
    EPS Estimate Drift
    90d ago$-0.11+17.0%
    60d ago$-0.11+17.0%
    30d ago$-0.11+17.5%
    7d ago$-0.13+2.1%
    Current$-0.13
    Revenue Consensus
    $0
    Range$0 - $0
    14 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.15
    Range$-0.21 - $-0.06
    11 analysts
    Revenue Consensus
    $1M
    Range$1M - $1M
    14 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.15---
    Sep 26EST
    		-$-0.13---
    Jun 26
    Reported Aug 6
    		$-0.13$-0.10-30.00%Miss+7.1%
    Mar 26
    Reported May 5
    		$-0.10$-0.10+0.00%Beat+16.7%
    Dec 25
    Reported Mar 5
    		$-0.09$-0.10+5.66%Beat+18.2%
    Sep 25
    Reported Nov 5
    		$-0.08$-0.14+42.86%Beat+0.0%
    Jun 25
    Reported Aug 11
    		$-0.14$-0.12-16.67%Miss-40.0%
    Mar 25
    Reported May 8
    		$-0.12$-0.11-9.09%Miss-50.0%
    Dec 24
    Reported Feb 27
    		$-0.11$-0.10-10.00%Miss+0.0%
    Sep 24
    Reported Nov 12
    		$-0.08$-0.11+27.27%Beat+0.0%
    Jun 24
    Reported Aug 12
    		$-0.10$-0.09-11.11%Miss-11.1%
    Mar 24
    Reported May 13
    		$-0.08$-0.11+27.27%Beat-33.3%
    Dec 23
    Reported Mar 21
    		$-0.11$-0.09-22.22%Miss-10.0%
    Sep 23
    Reported Nov 9
    		$-0.08$-0.11+27.27%Beat+33.3%
    Jun 23
    Reported Aug 3
    		$-0.09$-0.08-12.50%Miss-12.5%
    Mar 23
    Reported May 4
    		$-0.06$-0.11+45.45%Beat+14.3%
    Dec 22
    Reported Mar 15
    		$-0.10$-0.11+9.09%Beat+52.4%
    Sep 22
    Reported Nov 9
    		$-0.12$-0.12+0.00%Beat-20.0%
    Jun 22
    Reported Aug 1
    		$-0.08$-0.07-14.29%Miss+92.5%
    Mar 22
    Reported May 9
    		$-0.07$-0.13+46.15%Beat+50.0%
    Dec 21
    Reported Mar 21
    		$-0.21$-0.07-200.00%Miss-31.2%
    Sep 21
    Reported Nov 12
    		$-0.10$-0.11+9.09%Beat+44.4%
    Jun 21
    Reported Aug 16
    		$-1.07$-1.03-3.88%Miss-495.8%
    Mar 21
    Reported Apr 30
    		$-0.14N/AN/ABeat+65.7%
    Dec 20
    Reported Mar 5
    		$-0.16N/AN/ABeat+82.2%
    Sep 20
    Reported Nov 9
    		$-0.18N/AN/ABeat+81.1%
    Jun 20
    Reported Aug 13
    		$-0.18N/AN/ABeat+85.8%
    Mar 20
    Reported Jun 8
    		$-0.41N/AN/ABeat+69.3%
    Dec 19
    Reported Feb 13
    		$-0.90N/AN/ABeat-
    Sep 19
    Reported Nov 13
    		$-0.95N/AN/ABeat-
    Jun 19
    Reported Jul 1
    		$-1.27N/AN/ABeat-
    Mar 19
    Reported Jun 30
    		$-1.33N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-5.97EV/EBITDA-8.92x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-56.70%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio11.22xQuick Ratio11.22x
    Trading Statistics
    Beta0.82Avg Volume3.22M
    52-Week High$6.8852-Week Low$1.61

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.43
    SMA 20$2.30
    SMA 50$2.19
    SMA 200$4.03
    EMA 10$2.40
    EMA 20$2.33
    EMA 50$2.32
    EMA 200$3.23

    MACD

    Line: 0.09Signal: 0.08Hist: 0.01

    ADX

    ADX: 26.9+DI: 20.9-DI: 14.8

    Aroon & PSAR

    Aroon Up84.0
    Aroon Down28.0
    PSAR$2.55

    Bollinger Bands

    Upper Band$2.66
    Lower Band$1.94
    %B Position3134%(Upper)
    Band Width0.63

    RSI (14-Day)

    Neutral
    55.2

    Momentum Oscillators

    Stoch %K70.9
    Stoch %D79.0
    Williams %R-41.6
    ROC (10d)3.5%
    Momentum0.08
    CCI (20d)38.1
    MFI (14d)62.5

    Volatility Measures

    ATR (14d)$0.13(5.5%)
    StdDev (20d)0.18
    Hist Vol67.2%(High)

    Volume Flow

    VWAP$2.37
    OBV-36.3M
    AD Line-99.7M
    CMF (20d)0.298

    Volume Metrics

    Avg Vol (20d)3.2M
    Vol Ratio1.1x
    VWMA (20d)$2.26

    Pivot Points

    R3$2.58
    R2$2.55
    R1$2.47
    Pivot Point$2.44
    S1$2.36
    S2$2.33
    S3$2.25

    Advanced Oscillators

    TSI17.79
    Ultimate Osc59.2
    KST151.83

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$850,000$0$2.84M$0
    Cost of Revenue$0$0$370,000$0$0$0N/A$0$0$0$468,000$0
    Gross Profit$0$0$-370,000$0$0$0N/A$0$850,000$0$2.38M$0
    Operating Expenses$26.98M$20.30M$17.99M$15.82M$21.07M$17.97M$16.57M$12.24M$15.89M$12.77M$15.39M$11.93M
    R&D$19.58M$13.39M$13.67M$12.83M$16.41M$13.05M$13.03M$8.61M$11.17M$9.52M$12.43M$8.83M
    SG&A$7.40M$6.91M$4.32M$2.99M$4.65M$4.91M$3.54M$3.63M$4.72M$3.25M$2.96M$3.10M
    Operating Income$-26,979,000$-20,299,000$-17,990,000$-15,817,000$-21,066,000$-17,966,000$-16,571,000$-12,239,000$-15,045,000$-12,770,000$-15,389,000$-11,926,000
    Interest Income$0$0$0$0$0$0$0$0$0$0$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-25,154,000$-18,317,000$-15,716,000$-14,259,000$-19,881,000$-16,633,000$-15,031,000$-10,481,000$-13,076,000$-10,787,000$-13,415,000$-9,964,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-25,154,000$-18,317,000$-15,716,000$-14,259,000$-19,881,000$-16,633,000$-15,031,000$-10,481,000$-13,076,000$-10,787,000$-13,415,000$-9,964,000
    EBITDA$-24,572,000$-18,155,000$-16,542,000$-14,263,000$-19,616,000$-16,269,000$-14,942,000$-10,294,000$-13,337,000$-10,700,000$-13,759,000$-10,284,000
    EBIT$-25,154,000$-18,317,000$-15,716,000$-14,259,000$-19,881,000$-16,633,000$-15,031,000$-10,481,000$-13,076,000$-10,787,000$-13,415,000$-9,964,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about CMPX

    News

    Compass Therapeutics, Inc. (NASDAQ:CMPX) Given Average Rating of "Moderate Buy" by Analysts

    Compass Therapeutics, Inc. (NASDAQ:CMPX) has received an average "Moderate Buy" rating from sixteen research firms, with an average 12-month price target of $11.77. Despite this bullish sentiment from analysts, the company's shares are trading down 0.4% at $2.25, and it reported a quarterly loss of $0.13 per share, missing consensus estimates. Institutional investors hold a significant 68.43% of CMPX shares, with several firms recently increasing their positions.

    MarketBeat•8/15/26•
    Somewhat-Bullish

    Stifel Maintains Compass Therapeutics(CMPX.US) With Buy Rating, Maintains Target Price $6

    Stifel has reiterated its Buy rating on Compass Therapeutics (CMPX.US) and maintained its target price of $6. This indicates the firm's continued confidence in the company's prospects.

    Moomoo•8/14/26•
    Bullish

    Compass Therapeutics And 2 Other Promising Penny Stocks For Your Watchlist

    This article highlights three promising penny stocks for investors' watchlists: Compass Therapeutics (CMPX), Grab Holdings (GRAB), and Hyliion Holdings (HYLN). Despite varying financial statuses—from pre-revenue to strong growth—all three companies are presented with an overview of their operations, market capitalization, and key financial health indicators, emphasizing their potential for growth in a positive market trend.

    Simply Wall Street•8/14/26•
    Neutral

    Compass Therapeutics And 2 Other Promising Penny Stocks For Your Watchlist

    This article highlights three promising "penny stocks" with strong financial health: Compass Therapeutics (CMPX), Grab Holdings (GRAB), and Hyliion Holdings (HYLN). Despite their status as penny stocks, the companies demonstrate potential for growth and value backed by solid fundamentals. The analysis details their financial performance, market capitalization, and future prospects based on recent earnings and analyst forecasts.

    Simply Wall Street•8/14/26•
    Neutral

    We're Not Very Worried About Compass Therapeutics' (NASDAQ:CMPX) Cash Burn Rate

    This article assesses Compass Therapeutics' cash burn rate, concluding that despite a high burn rate relative to its market cap, the company has a substantial cash reserve that should last for over two years. The analysis suggests that while the burn rate is a factor, the current cash runway provides a significant buffer against immediate financial concerns.

    Moomoo•8/12/26•
    Bullish

    Frequently Asked Questions About CMPX

    Does CMPX pay dividends?
    Compass Therapeutics Inc. (CMPX) does not currently pay a regular dividend.
    What is CMPX's market cap?
    Compass Therapeutics Inc. (CMPX) has a market capitalization of $430.41M with a current stock price of $2.39.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In